Overall, it is recommended that the BRAF mutational status be confirmed at the time of both primary and metastatic cancer due to the distinctive biological subtype it confers, its poor prognostic association particularly in a MSS background, and that the majority of available data suggest that response to anti-EGFR therapy is less likely in mutant compared to wild-type BRAF cancers (Australian Cancer Guidelines 2017; http://www.cancer.org.au). The gene discussed is BRAF; the disease is metastatic malignant neoplasm.